MLNT - Melinta Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.5000
-0.0302 (-5.70%)
As of 4:00PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close0.5302
Open0.5150
Bid0.0000 x 800
Ask0.0000 x 900
Day's Range0.5000 - 0.5300
52 Week Range0.3000 - 10.1000
Volume695,087
Avg. Volume565,971
Market Cap6.875M
Beta (5Y Monthly)6.44
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • GlobeNewswire

    Melinta Therapeutics Announces Restructuring Support Agreement with its Secured Lenders under its Senior Credit Facility

    Melinta Therapeutics, Inc. (MLNT) (the “Company” or “Melinta”), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced that it has entered into a Restructuring Support Agreement (the “Agreement”) with the lenders under its senior credit facility, Deerfield Private Design Fund III, L.P. and Deerfield Private Design Fund IV, L.P. (the “Supporting Lenders”). Under the Agreement, the Supporting Lenders would acquire the Company as a going concern by exchanging $140 million of secured claims arising under its senior credit facility for 100 percent of the equity to be issued by the reorganized Company pursuant to a pre-negotiated chapter 11 plan of reorganization.

  • GlobeNewswire

    Melinta Therapeutics Files Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2019

    Melinta Therapeutics, Inc. (MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced that it has filed its quarterly report on Form 10-Q for the three and nine months ended September 30, 2019 with the Securities and Exchange Commission (“SEC”). The Company encourages its current and potential investors to read this quarterly report for information related to our third quarter 2019 financial results and other important corporate updates. A link to Melinta’s filings with the SEC can be found on its website at http://ir.melinta.com/financial-information/sec-filings.

  • GlobeNewswire

    Melinta Therapeutics Announces U.S. FDA Approval of Supplemental New Drug Application for BAXDELA® (delafloxacin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP)

    Melinta Therapeutics, Inc. (MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced the U.S. Food and Drug Administration (FDA) has approved BAXDELA® (delafloxacin) for the treatment of adult patients with community-acquired bacterial pneumonia (CABP) caused by designated susceptible bacteria. This supplemental approval follows FDA priority review based on the previous Qualified Infectious Disease Product (QIDP) designation, which provides certain incentives for the development of antibacterial and antifungal treatments for serious or life-threatening infections.

  • PR Newswire

    Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2019

    52 Presentations by Coalition Members During the Annual Meeting WASHINGTON , Oct. 1, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug-resistant ...

  • GlobeNewswire

    Melinta Therapeutics Announces Appointment of Jennifer Sanfilippo to Interim Chief Executive Officer and Director

    Melinta Therapeutics, Inc. (MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced that Jennifer Sanfilippo has been named interim chief executive officer and director, effective August 28, 2019. Prior to this appointment, Ms. Sanfilippo served as senior vice president and general counsel of Melinta. “Jennifer’s appointment to interim chief executive officer is the result of a thoughtful succession planning process undertaken by the board of directors.

  • GlobeNewswire

    Melinta Therapeutics Names David Gill as Chairman and Announces CEO Succession Plan

    Melinta Therapeutics, Inc. (MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced changes to its board of directors and executive management team. David Gill, a current Melinta board member, has been named chairman of the board of directors, effective immediately, succeeding Kevin Ferro, who voluntarily resigned from the position and the board of directors. John H. Johnson voluntarily resigned from his position as chief executive officer (CEO) due to changes in the Company’s circumstances and in order to pursue other opportunities.

  • GlobeNewswire

    Melinta Therapeutics Reports Second Quarter 2019 Financial Results and Provides Business Update

    ~ Revenue of $16.0 million, Including Net Product Sales of $13.8 million, for the Second Quarter 2019 ~ ~ Reduction of Operating Expenses of 32 Percent, or $16.3.

  • GlobeNewswire

    Melinta Therapeutics Announces Rescheduling of Second Quarter 2019 Financial Results Reporting

    Melinta Therapeutics, Inc. (MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced that it will report its second quarter 2019 financial results on Friday, August 9, 2019. The Company also announced that it will cancel its 2019 second quarter conference call, which had been previously scheduled for Wednesday, August 7, 2019, at 8:30 a.m. ET. Melinta Therapeutics, Inc. is the largest pure-play antibiotics company, dedicated to saving lives threatened by the global public health crisis of bacterial infections through the development and commercialization of novel antibiotics that provide new therapeutic solutions.

  • GlobeNewswire

    Melinta Therapeutics Announces Preliminary Second Quarter 2019 Financial Results and Provides Corporate Update

    Melinta Therapeutics, Inc. (MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today reported preliminary and unaudited financial results and provided a corporate update for the second quarter ended June 30, 2019. “Melinta’s preliminary second quarter 2019 results demonstrate that the actions taken to improve upon the Company's operational and financial efficiencies are continuing to drive progress,” said John H. Johnson, chief executive officer of Melinta.

  • PR Newswire

    X-Biotix Therapeutics Joins Antimicrobials Working Group

    WASHINGTON , July 1, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the addition of X-Biotix Therapeutics, Inc. (X-Biotix) to its coalition of companies with the mission to ...

  • PR Newswire

    Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2019

    64 Presentations by Coalition Members During the Annual Meeting WASHINGTON , June 20, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug-resistant ...

  • GlobeNewswire

    Melinta Therapeutics Announces U.S. FDA Acceptance of Supplemental New Drug Application for BAXDELA® (delafloxacin) for the Treatment of Community-Acquired Bacterial Pneumonia

    Melinta Therapeutics, Inc. (MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced the U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for BAXDELA® (delafloxacin) for priority review. The sNDA filing seeks to expand the current indication for BAXDELA to include adult patients with community-acquired bacterial pneumonia (CABP). The FDA granted priority review status based on the previous Qualified Infectious Disease Product (QIDP) designation, which provides certain incentives for the development of antibacterial and antifungal treatments for serious or life-threatening infections.

  • PR Newswire

    Antimicrobials Working Group Commends Senator Isakson and Senator Casey for Introducing Legislation to Improve Access to Innovative Therapies to Fight Drug-Resistant Infections

    The DISARM Act of 2019 provides the framework needed to stabilize the antimicrobial ecosystem, spur development of new infection-fighting drugs, and preserve the effectiveness of existing medicines for ...

  • GlobeNewswire

    Melinta Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update

    ~ Revenue of $14.1 million, Including Net Product Sales of $11.8 million, for the First Quarter 2019 ~ ~ Reduction of Operating Expenses of 34 Percent, or $19.8 million,.

  • GlobeNewswire

    Melinta Therapeutics to Present at Making a Difference in Infectious Diseases (MAD-ID) 2019 Annual Meeting

    Melinta Therapeutics, Inc. (MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, announced today that it will present data on its portfolio, including results from its real-world registry studies of VABOMERE® (meropenem and vaborbactam), ORBACTIV® (oritavancin), and MINOCIN® (minocycline) for Injection at the upcoming Making a Difference in Infectious Diseases (MAD-ID) 2019 Annual Meeting held from May 8-11 2019 in Orlando, Florida. "Our presentations demonstrate Melinta’s continued commitment to combatting antimicrobial resistance by helping to inform clinical decision-making for the responsible and sustainable use of our antibiotics,” said Sue Cammarata, M.D., chief medical officer of Melinta.

  • GlobeNewswire

    Melinta Therapeutics to Report First Quarter 2019 Financial Results on May 9, 2019

    Melinta Therapeutics, Inc. (MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced it intends to release its first quarter 2019 financial results on May 9, 2019, after the close of the U.S. financial markets. Melinta will host a conference call and live webcast on Thursday, May 9, 2019, at 4:30 p.m. ET to discuss its financial results and provide a business update. On May 9, 2019 at 4:30 p.m. ET, the live call may be accessed by dialing 877-377-7553 for domestic callers and 253-237-1151 for international callers and using conference ID #5233509.

  • PR Newswire

    Antimicrobials Working Group Highlights Member Company Participation at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

    78 Presentations by Coalition Members During the Annual Meeting WASHINGTON , April 12, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug-resistant ...

  • GlobeNewswire

    Melinta Therapeutics Announces Multiple Presentations at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

    Melinta Therapeutics, Inc. (MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced that researchers are scheduled to present multiple scientific data presentations with data from its antibiotic portfolio at this year’s 29th European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), April 13-16 in Amsterdam, Netherlands. “The body of data presented at ECCMID represents an important step in the global fight against antimicrobial resistance and delivering anti-infective solutions to patients,” said Sue Cammarata, M.D., chief medical officer of Melinta.

  • GlobeNewswire

    Melinta Therapeutics Reports Fourth Quarter and Full-Year 2018 Financial Results

    ~ Reports Revenue of $96.4 million, Including Net Product Sales of $46.6 million, for the Full-Year 2018 ~ ~ Net Product Sales of $14.6 million for the Fourth Quarter of 2018,.

  • GlobeNewswire

    Melinta Therapeutics to Report Fourth Quarter and Year-End 2018 Financial Results on March 13, 2019

    Melinta Therapeutics, Inc. (MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced it intends to release its fourth quarter and year-end 2018 financial results on March 13, 2019, after the close of the U.S. financial markets. Melinta will host a conference call and live webcast on Wednesday, March 13, 2019 at 4:30 p.m. ET to discuss its financial results and provide a business update. On March 13, 2019 at 4:30 p.m. ET, the live call may be accessed by dialing 877-377-7553 for domestic callers and 253-237-1151 for international callers and using conference ID #1698998.

  • GlobeNewswire

    Melinta Therapeutics Announces Closing of Initial $75 Million Vatera Convertible Loan Funding

    MORRISTOWN, N.J., Feb. 25, 2019 (GLOBE NEWSWIRE) --  Melinta Therapeutics, Inc. (MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced the closing and receipt of the initial $75 million disbursement under the previously announced convertible loan facility from Vatera Healthcare Partners LLC on February 22, 2019. In addition, the previously announced amendment to the facility agreement with funds managed by Deerfield Management Company, L.P. (collectively, “Deerfield”) also became effective.

  • GlobeNewswire

    Melinta Therapeutics Announces One-for-Five Reverse Stock Split

    Melinta Therapeutics, Inc. (MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced that its Board of Directors has approved a one-for-five reverse stock split of the Company's common stock, par value $0.001. The reverse stock split, which was approved by the Company's stockholders at a special meeting held on February 19, 2019, will be effective at 5:00 pm Eastern Time today.

  • GlobeNewswire

    Melinta Therapeutics Provides Corporate Updates

    Melinta Therapeutics, Inc. (MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today provided an update on its strategic repositioning initiatives, cost savings outlook, as well as new management appointments. The Company continues to execute on its strategic initiatives aimed at repositioning the business to drive profitable growth and value creation. “We have been moving with purpose and focus over the past several months to reposition Melinta and set a new trajectory towards growth and value creation,” said John H. Johnson, interim chief executive officer and director of Melinta Therapeutics.